New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 27, 2011
14:07 EDTMRKEarnings Preview: Merck trading up ahead of Q3 earnings
Merck (MRK) is expected to report Q3 earnings before the market open on Friday, October 28 with a conference call scheduled for 8:00 am ET. Analysts are looking for EPS of 91c on revenue of $11.61B. The consensus range is 83c-93c for EPS, and $11.47B-$11.95B for revenue, according to First Call. In Q2, Merck reported in-line EPS and better-than-expected revenue. It also reported sales growth for Singular, Remicade, and Animal Health, while raising the full-year EPS to $3.68-$3.76. In its previous conference call, the company announced plans to reduce the workforce by 12%-13% by 2015. The measure would save the company $3.5B by the end of FY12. To accelerate the goal, the Associated Press reported the company may speed up the layoffs to reach that goal. In the previous quarter, Merck announced positive clinical results for several drugs: Isentress, Delura, Odanacatib, and Gardasil. In fact, the CDC voted to expand the use of Gardasil. Investors will also look for updates on the progress of its new type 2 diabetes treatment Juvisync, which recently received FDA approval. Meanwhile, the company signed various research and colloboration agreements with AbD Serotec, Serum Institute of India, and BGI. The company may also mention its sale of its 50% interest in the Johnson & Johnson-Merck joint venture for $175M. Merck was upgraded to Buy at Jeffries, citing valuation and capital allocation. Barron's also said Merck was attractive for its dividend yield, restructuring savings, and expansion in emerging markets.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:31 EDTMRKMerck announces collaboration with American Diabetes Association
Merck announced a collaboration with the American Diabetes Association. The collaboration aims to educate adults with diabetes about their increased risk for potentially serious health problems, including pneumococcal pneumonia, influenza and hepatitis B, making it important for people with Type 1 or Type 2 diabetes to talk to their health care professional about these diseases.
March 25, 2015
07:28 EDTMRKOptions expected to be active
Subscribe for More Information
March 24, 2015
19:40 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
17:02 EDTMRKMerck announces new $10B share repurchase program
Merck announced that its board of directors has authorized additional purchases of up to $10B of Merck’s common stock for its treasury. The treasury stock purchase has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. With this announcement, the company’s total outstanding share repurchase authorization is now approximately $11.7B, which includes approximately $1.7B in authorized repurchases remaining under the program previously announced on May 1, 2013. Merck continues to expect average diluted shares outstanding will be approximately 2.86B in 2015.
17:00 EDTMRKMerck announces new $10B share repurchase program
Subscribe for More Information
16:00 EDTMRKOptions Update; March 24, 2015
iPath S&P 500 VIX Short-Term Futures down 10c to 25.14 Option volume leaders: AAPL TSLA TWTR GILD FB AMAT GOOG C MRK GILD according to Track Data.
08:31 EDTMRKMerck: Phase 3 KEYNOTE-006 study met co-primary endpoints, will be stopped early
Subscribe for More Information
March 23, 2015
09:45 EDTMRKUBS to hold a field trip
Subscribe for More Information
07:17 EDTMRKAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
07:41 EDTMRKAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 16, 2015
15:33 EDTMRKMerck says study shows VYTORIN reduced CV events more than simvastatin alone
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use